This is a working overview of lactam bridge, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-13. Anything still debated is marked as such rather than presented as settled.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved for therapeutic use | No marketing authorisation from major agencies |
| Legal classification | Varies by jurisdiction | Prescription-only or controlled in several countries |
| Common synonyms | Melanotan II; MT-II | Also referenced by catalogue codes |
| Typical analytical method | Reverse-phase HPLC | Often paired with mass spectrometry |
| Primary literature focus | Receptor pharmacology | Pigmentation and melanocortin signalling |
Reversed-phase high-performance liquid chromatography is the routine method for purity assessment. Peptides absorb near 214 nm because of the peptide bond, and a gradient of acetonitrile in water separates the intact peptide from deletion sequences, oxidised products, and earlier-eluting fragments at neutral pH. Electrospray ionisation mass spectrometry provides an orthogonal check: the measured mass must agree with the theoretical value. Amino acid analysis and peptide mapping confirm structure but are used less often. Reference standards remain scarce because the peptide is not described in any pharmacopoeia.
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Lyophilised peptide powder is comparatively stable when kept dry, cold and protected from light. Once dissolved, the molecule is exposed to hydrolysis, oxidation and microbial growth, and degradation accelerates at higher temperatures and in alkaline solution. Repeated freeze-thaw cycles concentrate solutes and promote aggregation. Handling guidance for research peptides commonly clusters around freezer temperatures for powder and short refrigerated use for reconstituted solutions, with pH control and sterile technique applied throughout.
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
== Research == Moxidectin is being evaluated as a treatment for scabies. It is established in veterinary medicine to treat a range of parasites, including sarcoptic mange. Its advantage over ivermectin is its longer half-life in humans, thus the potential duration of action.
6-carboxytetrahydropterin synthase (EC 4.1.2.50, CPH4 synthase, queD (gene), ToyB, ykvK (gene)) is an enzyme with systematic name 7,8-dihydroneopterin 3'-triphosphate acetaldehyde-lyase (6-carboxy-5,6,7,8-tetrahydropterin and triphosphate-forming). This enzyme catalyses the following reversible chemical reaction. 7,8-dihydroneopterin 3′-triphosphate + H2O ⇌ 6-carboxy-5,6,7,8-tetrahydropterin + acetaldehyde + triphosphate This enzyme binds Zn2+. It is isolated from the bacteria Bacillus subtilis and Escherichia coli. The stimulation is part of the biosynthesis pathway of queuosine. The enzyme from Escherichia coli can also convert 6-pyruvoyl-5,6,7,8-tetrahydropterin and sepiapterin to 6-carboxy-5,6,7,8-tetrahydropterin. Media related to 6-carboxytetrahydropterin synthase at Wikimedia Commons 6-carboxytetrahydropterin+synthase at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
== Astrophysical dating == Knowledge of current and theoretical production ratios of uranium-235 to uranium-238 allows radiometric dating, the time since modern uranium nuclei were formed in stellar nucleosynthesis. The 1957 B2FH landmark paper in astrophysics explained the r-process by which both nuclei form. The authors predicted their relative abundances, and those of their rapidly alpha-chain decaying parent nuclides. Thus they predicted 1.64 as the 235U/238U ratio contributed to the interstellar medium by r-process events (supernovae and subsequently discovered kilonovae). This takes billions of years to diminish to their present value of 0.0072 (see natural uranium). They investigate scenarios for historical contribution to the solar nebula, before contribution is cut off at the Sun's formation 4.5 billion years ago. The scenarios are: a single supernova, a finite continuous uniform series of supernovae representing the lifetime of the Milky Way, and an infinite series representing the steady-state universe. From the second scenario, they estimated an age of the Milky Way at around 10 billion years, compared to a modern value of 13.61 billion years. At the time, the oldest known objects were globular clusters, of which the oldest were estimated to be about 6.5 billion years old.
Sources: en.wikipedia.org
==== Majors and programs ==== Doctoral Communication Sciences and Disorders Audiology Physical Therapy Master's Communication Sciences and Disorders Speech-language Pathology Genetic Counseling Health Administration (in conjunction with the College of Medicine and the Lindner College of Business) Nutrition Sciences Transfusion and Transplantation Services Bachelor's Advanced Medical Imaging Technology Clinical Laboratory Science Clinical Laboratory Science – Distance Learning Communication Sciences and Disorders Dietetics Food and Nutrition Concentration in Exercise Science Concentration in Pre-Medicine Health Information Management – Distance Learning Health Sciences Sports and Biomechanics Concentration Exercise Science Concentration Certificate Clinical Laboratory Science Dietetics School of Social Work
=== Bleeding esophageal varices === Octreotide is often given as an infusion for management of acute hemorrhage from esophageal varices in liver cirrhosis on the basis that it reduces portal venous pressure, though current evidence suggests that this effect is transient and does not improve survival.
== A posteriori therapeutic drug monitoring == The concept of a posteriori TDM corresponds to the usual meaning of TDM in medical practice, which refers to the readjustment of the dosage of a given treatment in response to the measurement of an appropriate marker of drug exposure or effect. TDM encompasses all aspects of this feedback control, namely:
== External links == Frontline: Dangerous prescriptions – Interview with Leo Lutwak, in which he discusses the side effects of fenfluramine (Pondimin), its successor dexfenfluramine (Redux), and the fen-phen combination. U.S. FDA fen-phen information Tellier P (November 2001). "Fenfluramines, idiopathic pulmonary primary hypertension and cardiac valve disorders: facts and artifacts". Annales de Médecine Interne. 152 (7): 429–36. PMID 11965083.
Sources: en.wikipedia.org
The Wisconsin Sleep Cohort Study estimated in 1993 that roughly one in every 15 Americans was affected by at least moderate sleep apnea. It also estimated that in middle-age as many as 9% of women and 24% of men were affected, undiagnosed and untreated. The costs of untreated sleep apnea reach further than just health issues. It is estimated that in the U.S., the average untreated sleep apnea patient's annual health care costs $1,336 more than an individual without sleep apnea. This may cause $3.4 billion/year in additional medical costs. Whether medical cost savings occur with treatment of sleep apnea remains to be determined.
== Ligand variations == Since the initial MPAA ligand report, many variations of bifunctional ligands derived from amino acids have been developed. Bidentate MPAQ (mono-protected amino quinoline) ligands were introduced in the application of β-methylene C–H bonds in aliphatic amides. The highly successful MPAO (mono-protected amino oxazoline) ligand allowed for C(sp3)–H functionalization via arylation of α-methyls, borylation of cyclobutyl carboxylic amides, and boronic cross coupling of alkyl amines. MPAAM (mono-protected aminoalkyl amine) ligands were used in enantioselective C(sp3)–H arylations of free aliphatic acids without the need for exogenous directing groups. Variations of the MPAAThio (mono-protected aminoalkyl thioether) ligands have been use in olefination of free carboxylic acids and arylation, carbonylation, and olefination of free aliphatic amines. Expanding the reaction substrate scope to non-directed C(sp2)–H bonds, pyridone ligands were developed to functionalize arenes and heteroarenes which proved to be particularly useful in late-state derivatization of bioactive compounds such as estrone, caffeine, and camptothecin. Many analogues of the pyridine-pyridone (azine-pyridone) ligands were developed and used in the C(sp2)–H hydroxylation of (hetero)arenes and the dehydrogenation of methylene C(sp3)–H bonds on alkyl free acids.
The human dilemma is hardly new. We find ourselves through no wish of our own on this slowly revolving planet in an obscure corner of a vast universe. Our questioning intelligence will not let us live in cow-like content with our lot. We have a deep need to know why we are here. What is the world made of? More important, what are we made of? In the past religion answered these questions, often in considerable detail. Now we know that almost all these answers are highly likely to be nonsense, having sprung from man's ignorance and his enormous capacity for self-deception ... The simple fables of the religions of the world have come to seem like tales told to children. Even understood symbolically they are often perverse, if not rather unpleasant ... Humanists, then, live in a mysterious, exciting and intellectually expanding world, which, once glimpsed, makes the old worlds of the religions seem fake-cosy and stale Crick was especially critical of Christianity:
Sources: en.wikipedia.org
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.
Much of the evidence comes from case reports and accounts of unregulated use rather than controlled trials. Differences in product purity and dosing add further variability.
Laboratory work focuses on receptor binding and cellular signalling. Observational reports document outcomes after use, and analytical chemists examine samples to assess content and purity.
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.